Hot topics in reactive oxygen therapy : Antimicrobial and immunological mechanisms, safety and clinical applications
Copyright © 2017 International Society for Chemotherapy of Infection and Cancer. All rights reserved..
Reactive oxygen species (ROS), when combined with various delivery mechanisms, has the potential to become a powerful novel therapeutic agent against difficult-to-treat infections, especially those involving biofilm. It is important in the context of the global antibiotic resistance crisis. ROS is rapidly active in vitro against all Gram-positive and Gram-negative bacteria tested. ROS also has antifungal and antiviral properties. ROS prevents the formation of biofilms caused by a range of bacterial species in wounds and respiratory epithelium. ROS has been successfully used in infection prevention, eradication of multiresistant organisms, prevention of surgical site infection, and intravascular line care. This antimicrobial mechanism has great potential for the control of bioburden and biofilm at many sites, thus providing an alternative to systemic antibiotics on epithelial/mucosal surfaces, for wound and cavity infection, chronic respiratory infections and possibly recurrent urinary infections as well as local delivery to deeper structures and prosthetic devices. Its simplicity and stability lend itself to use in developing economies as well.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Journal of global antimicrobial resistance - 8(2017) vom: 15. März, Seite 194-198 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dryden, Matthew [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Infective Agents |
|---|
| Anmerkungen: |
Date Completed 17.12.2018 Date Revised 17.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jgar.2016.12.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM269143009 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM269143009 | ||
| 003 | DE-627 | ||
| 005 | 20231224224010.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jgar.2016.12.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0897.xml |
| 035 | |a (DE-627)NLM269143009 | ||
| 035 | |a (NLM)28219826 | ||
| 035 | |a (PII)S2213-7165(17)30024-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dryden, Matthew |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hot topics in reactive oxygen therapy |b Antimicrobial and immunological mechanisms, safety and clinical applications |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.12.2018 | ||
| 500 | |a Date Revised 17.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 International Society for Chemotherapy of Infection and Cancer. All rights reserved. | ||
| 520 | |a Reactive oxygen species (ROS), when combined with various delivery mechanisms, has the potential to become a powerful novel therapeutic agent against difficult-to-treat infections, especially those involving biofilm. It is important in the context of the global antibiotic resistance crisis. ROS is rapidly active in vitro against all Gram-positive and Gram-negative bacteria tested. ROS also has antifungal and antiviral properties. ROS prevents the formation of biofilms caused by a range of bacterial species in wounds and respiratory epithelium. ROS has been successfully used in infection prevention, eradication of multiresistant organisms, prevention of surgical site infection, and intravascular line care. This antimicrobial mechanism has great potential for the control of bioburden and biofilm at many sites, thus providing an alternative to systemic antibiotics on epithelial/mucosal surfaces, for wound and cavity infection, chronic respiratory infections and possibly recurrent urinary infections as well as local delivery to deeper structures and prosthetic devices. Its simplicity and stability lend itself to use in developing economies as well | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Novel antimicrobial | |
| 650 | 4 | |a Reactive oxygen species | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 700 | 1 | |a Cooke, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Salib, Rami |e verfasserin |4 aut | |
| 700 | 1 | |a Holding, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Pender, Sylvia L F |e verfasserin |4 aut | |
| 700 | 1 | |a Brooks, Jill |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of global antimicrobial resistance |d 2013 |g 8(2017) vom: 15. März, Seite 194-198 |w (DE-627)NLM237523876 |x 2213-7173 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2017 |g day:15 |g month:03 |g pages:194-198 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jgar.2016.12.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2017 |b 15 |c 03 |h 194-198 | ||